IFEX Drug Patent Profile

Which patents cover Ifex, and when can generic versions of Ifex launch?

Ifex is a drug marketed by Baxter Hlthcare and is included in one NDA.

The generic ingredient in IFEX is ifosfamide; mesna. There are five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ifosfamide; mesna profile page.

Summary for IFEX

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	130
Patent Applications:	4,856
Drug Prices:	Drug price information for IFEX
What excipients (inactive ingredients) are in IFEX?	IFEX excipients list
DailyMed Link:	IFEX at DailyMed

See drug prices for IFEX

Pharmacology for IFEX

Drug Class	Alkylating Drug
Mechanism of Action	Alkylating Activity

US Patents and Regulatory Information for IFEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	IFEX	ifosfamide	INJECTABLE;INJECTION	019763-001	Dec 30, 1988	AP	RX	Yes	No
Baxter Hlthcare	IFEX/MESNEX KIT	ifosfamide; mesna	INJECTABLE;INJECTION	019763-004	Oct 10, 1992		DISCN	No	No
Baxter Hlthcare	IFEX	ifosfamide	INJECTABLE;INJECTION	019763-002	Dec 30, 1988	AP	RX	Yes	No

Expired US Patents for IFEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Baxter Hlthcare	IFEX	ifosfamide	INJECTABLE;INJECTION	019763-001	Dec 30, 1988
Baxter Hlthcare	IFEX	ifosfamide	INJECTABLE;INJECTION	019763-002	Dec 30, 1988
Baxter Hlthcare	IFEX	ifosfamide	INJECTABLE;INJECTION	019763-002	Dec 30, 1988

International Patents for IFEX

See the table below for patents covering IFEX around the world.

Country	Patent Number	Title	Estimated Expiration
Israel	28263	CYCLIC PHOSPHORIC ACID DERIVATIVES AND THEIR PRODUCTION
Israel	107187	Stable injectable mesna solutions
Norway	784192

IFEX Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for IFEX

Introduction to IFEX

IFEX, also known as ifosfamide, is an alkylating agent used in the treatment of various types of cancer, including testicular cancer. It is often administered in combination with other antineoplastic agents for third-line chemotherapy of germ cell testicular cancer[4].

Market Size and Growth

The global testicular cancer drugs market, within which IFEX operates, is expected to grow significantly. According to a report by Technavio, the market is projected to grow by USD 421 million during the period of 2019-2023, with a CAGR of over 4%[1].

Key Drivers of Market Growth

Several factors are driving the growth of the testicular cancer drugs market, including:

Availability of Combination Therapies

The effectiveness of combination therapies in treating testicular cancer is a major driver. IFEX, when used in combination with other approved antineoplastic agents, has shown significant improvement in patient survival rates. Researchers are focusing on developing new combination therapies due to their enhanced efficacy[1].

Early Detection and Diagnostic Methods

Advancements in diagnostic methods for early detection of testicular cancer are also boosting market growth. Early detection increases the likelihood of successful treatment, thereby increasing the demand for drugs like IFEX[1].

Major Players in the Market

Several pharmaceutical companies are key players in the testicular cancer drugs market, including:

Baxter

Baxter is one of the major companies offering IFEX for the treatment of testicular cancer. The company's product is indicated for use in combination with other approved antineoplastic agents[1].

Other Key Players

Other notable companies in this market include Bristol-Myers Squibb, Eli Lilly, Pfizer, and Teva Pharmaceutical, each offering different drugs for testicular cancer treatment[1].

Regional Market Outlook

The testicular cancer drugs market is segmented geographically into Asia, Europe, North America, and the Rest of the World (ROW). Each region presents different market dynamics and growth opportunities:

North America

North America is a significant market due to advanced healthcare infrastructure and high awareness of cancer treatments.

Europe and Asia

Europe and Asia are also crucial regions, with Europe having a well-established healthcare system and Asia showing rapid growth due to increasing healthcare expenditure and awareness[1].

Pricing and Cost Considerations

The cost of IFEX can vary based on several factors, including the pharmacy and the patient's insurance status.

Current Pricing

The cost for IFEX 1 g intravenous powder for injection is around $48 for a single dose, with generic versions available at slightly lower prices, such as $45.44 for 1 powder for injection[5].

Financial Assistance Programs

To make the drug more accessible, financial assistance programs, coupons, and copay cards are available to help cover the costs of IFEX for eligible patients[5].

Dosage and Administration

IFEX is administered as a slow intravenous infusion, typically at a dose of 1.2 grams per square meter per day for 5 consecutive days. Treatment is repeated every 3 weeks or after recovery from hematologic toxicity. Extensive hydration and the use of mesna are recommended to prevent bladder toxicity[4].

Side Effects and Safety Considerations

IFEX has several side effects, including myelosuppression, urotoxicity, nausea, vomiting, and central nervous system toxicities. Close clinical monitoring is necessary to manage these side effects effectively[2][4].

Clinical Efficacy

Studies have shown that IFEX, when used in combination with other chemotherapy agents, can significantly improve survival rates for patients with germ cell testicular cancer. For example, a study at Indiana University demonstrated that 10 out of 50 fully evaluable patients were still alive 2 to 5 years after treatment with IFEX in combination with cisplatin and either vinblastine or etoposide[2].

Market Challenges

Despite the growth potential, the market faces several challenges:

Supply Chain Issues

Ensuring a stable supply of IFEX and other cancer drugs is crucial. However, supply chain disruptions and shortages can impact market growth and patient access to these medications[3].

Cost and Accessibility

The high cost of cancer treatments, including IFEX, can be a barrier to access for many patients. Financial assistance programs and generic versions can help mitigate this issue but do not fully address the problem[5].

Future Outlook

The future of IFEX and the broader testicular cancer drugs market looks promising due to ongoing research and development in combination therapies and early detection methods. As healthcare infrastructure improves globally, the demand for effective cancer treatments is expected to increase.

Key Takeaways

• The global testicular cancer drugs market is expected to grow by USD 421 million during 2019-2023.
• Combination therapies, including IFEX, are driving market growth due to their effectiveness.
• Early detection methods are also boosting the market.
• Major players like Baxter, Bristol-Myers Squibb, Eli Lilly, Pfizer, and Teva Pharmaceutical are key to the market.
• Pricing and accessibility remain significant challenges.
• IFEX is administered intravenously with specific dosing and safety protocols.

FAQs

Q: What is IFEX used for? IFEX (ifosfamide) is used in combination with other approved antineoplastic agents for the third-line chemotherapy of germ cell testicular cancer[4].

Q: How is IFEX administered? IFEX is administered as a slow intravenous infusion at a dose of 1.2 grams per square meter per day for 5 consecutive days, repeated every 3 weeks or after recovery from hematologic toxicity[4].

Q: What are the common side effects of IFEX? Common side effects include myelosuppression, urotoxicity, nausea, vomiting, and central nervous system toxicities[2][4].

Q: How much does IFEX cost? The cost of IFEX 1 g intravenous powder for injection is around $48, with generic versions available at slightly lower prices[5].

Q: Are there any financial assistance programs for IFEX? Yes, financial assistance programs, coupons, and copay cards are available to help cover the costs of IFEX for eligible patients[5].

Cited Sources

1. Technavio: Testicular Cancer Drugs Market 2019-2023 | Technavio - BioSpace
2. FDA: IFEX - accessdata.fda.gov
3. Goldman Sachs: Weighing the GLP-1 market - Goldman Sachs
4. Baxter Healthcare: IFEX- ifosfamide injection, powder, for solution Baxter Healthcare ...
5. Drugs.com: Ifex Prices, Coupons, Copay Cards & Patient Assistance - Drugs.com